Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?

被引：0
|
作者：
Tfelt-Hansen, Peer [1 ,2 ]
机构：
[1] Univ Copenhagen, Glostrup Hosp, Danish Headache Ctr, Dept Neurol, DK-2600 Glostrup, Denmark
[2] Univ Copenhagen, DK-2600 Glostrup, Denmark
来源：
CEPHALALGIA | 2011年 / 31卷 / 11期
关键词：
TRIAL;
D O I：
10.1177/0333102411398154
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1240 / 1240
页数：1
相关论文
共 50 条
  • [1] Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine
    David W. Dodick
    Giorgio Sandrini
    Paul Williams
    [J]. CNS Drugs, 2007, 21 : 73 - 82
  • [2] Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
    Dodick, David W.
    Sandrini, Giorgio
    Williams, Paul
    [J]. CNS DRUGS, 2007, 21 (01) : 73 - 82
  • [3] Evaluation of combination therapy (sumatriptan/naproxen sodium) versus monotherapy for the acute treatment of migraine using a novel clinical endpoint: Sustained pain free and no adverse events
    Landy, Stephen
    White, Jonathan D.
    Lener, Shelly E.
    McDonald, Susan A.
    [J]. NEUROLOGY, 2008, 70 (11) : A353 - A354
  • [4] Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan
    Dodick, David W.
    Kost, James
    Assaid, Christopher
    Lines, Christopher
    Ho, Tony W.
    [J]. CEPHALALGIA, 2011, 31 (03) : 296 - 300
  • [5] Total Migraine Freedom: A Potential Primary Endpoint To Assess Acute Treatment in Migraine
    Ho, T. W.
    Rodgers, A.
    Hustad, C. M.
    Cady, R. K.
    Martin, V. T.
    Winner, P.
    Ramsey, K. E.
    [J]. HEADACHE, 2010, 50 : S77 - S77
  • [6] Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, MK-0974, and zolmitriptan
    Dodick, D. W.
    Galet, V
    Kost, J.
    Assaid, C.
    Ho, T. W.
    [J]. HEADACHE, 2008, 48 : S41 - S42
  • [7] Total migraine freedom: a potential primary endpoint to assess acute treatment of migraine in the avitriptan program
    Marcus, R.
    Manos, G.
    [J]. CEPHALALGIA, 2011, 31 (01) : 79 - 80
  • [8] Total Migraine Freedom: A Potential Primary Endpoint To Assess Acute Treatment of Migraine in the Avitriptan Program
    Marcus, R. N.
    Manos, G.
    Tong, G.
    [J]. HEADACHE, 2011, 51 : 2 - 2
  • [9] Risk for Clinically Relevant Adverse Cardiac Events in Patients With Chest Pain at Hospital Admission
    Weinstock, Michael B.
    Weingart, Scott
    Orth, Frank
    VanFossen, Douglas
    Kaide, Colin
    Anderson, Judy
    Newman, David H.
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (07) : 1207 - 1212
  • [10] Acute migraine therapy with frovatriptan vs. sumatriptan: comparison based on sustained pain-free response with no adverse events
    Campbell, J.
    Harper, S.
    Hu, X.
    [J]. CEPHALALGIA, 2009, 29 : 18 - 19
12345